[go: up one dir, main page]

AR095431A1 - Formulaciones de fviii recombinante - Google Patents

Formulaciones de fviii recombinante

Info

Publication number
AR095431A1
AR095431A1 ARP140100977A ARP140100977A AR095431A1 AR 095431 A1 AR095431 A1 AR 095431A1 AR P140100977 A ARP140100977 A AR P140100977A AR P140100977 A ARP140100977 A AR P140100977A AR 095431 A1 AR095431 A1 AR 095431A1
Authority
AR
Argentina
Prior art keywords
rfviii
formulations
bdd
mutant
peg
Prior art date
Application number
ARP140100977A
Other languages
English (en)
Inventor
Tsvetkova Nelly
Ma Xinghang
Wang Deqian
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095431A1 publication Critical patent/AR095431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan formulaciones de rFVIII líquidas y Iiofilizadas, incluyendo formulaciones de rFVIII de longitud completa (FL-rFVIII), formulaciones de rFVIII con el dominio B eliminado (BDD-rFVIII), y formulaciones de mutante BDD-rFVIII (mutante BDD-rVIII). También se proporcionan formulaciones de rFVIII PEGilado líquidas y Iiofilizadas (PEG-rFVIII), incluyendo formulaciones de rFVIII de longitud completa PEGilado (PEG-FL-rFVIII), formulaciones de rFVIII con dominio B eliminado PEGilado (PEG-BDD-rFVIII), y formulaciones de mutante BDD-rFVIII PEGilado (mutante PEG-BDD-rFVIII).
ARP140100977A 2013-03-15 2014-03-13 Formulaciones de fviii recombinante AR095431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095431A1 true AR095431A1 (es) 2015-10-14

Family

ID=56119099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100977A AR095431A1 (es) 2013-03-15 2014-03-13 Formulaciones de fviii recombinante

Country Status (2)

Country Link
US (1) US20140274902A1 (es)
AR (1) AR095431A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025509284A (ja) * 2022-03-08 2025-04-11 コネクスト カンパニー リミテッド コラゲナーゼ、カルシウム、ヒスチジン及びグリシンを含む組成物及びコラゲナーゼの安定化方法

Also Published As

Publication number Publication date
US20140274902A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
MX386802B (es) Vectores del factor viii del virus adeno-asociado.
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2016001093A (es) Nanoemulsion de aminosilicona.
MX2016001094A (es) Nanoemulsion de aminosilicona.
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
TR201900274T4 (tr) Geliştirilmiş adenovirüs formülasyonları.
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
MX377022B (es) Composiciones de lágrimas artificiales.
EP3723771A4 (en) Recombinant adenoviruses and uses thereof
UY35412A (es) Formulaciones de fviii recombinante
HUE050362T2 (hu) Javított rekombináns fehérje expresszió hibrid CHEF1 promótert alkalmazva
EP2948469A4 (en) STABILIZED HEPATITIS B CORE POLYPEPTIDE
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
AR095431A1 (es) Formulaciones de fviii recombinante
UY4239Q (es) Silla con respaldo en forma de t
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
FR3004038B1 (fr) Architecture d'interface entre sous ensembles numerique et radio.
EP2985376A4 (en) CORE MATERIAL FOR A VACUUM INSULATION BODY WITH ORGANIC SYNTHETIC FIBERS AND VACUUM INSULATION BODIES THEREWITH
EA201891475A1 (ru) Система механической фиксации панелей пола
UA86172U (en) Suppository

Legal Events

Date Code Title Description
FB Suspension of granting procedure